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Abstract
Background: The objective of this analysis was to measure changes in items on the Pediatric
Adverse Event Rating Scale (PAERS) that relate to emotional well-being of children and adolescents
with Attention-Deficit/Hyperactivity Disorder (ADHD) during treatment with atomoxetine for up
to 24 weeks from the perspective of the patient, the parent, and the physician.
Methods: Patients aged 6–17 years with ADHD were treated with atomoxetine (target dose 1.2
mg/kg/day). In the two studies on which this secondary analysis is based the PAERS was used to
assess the tolerability of atomoxetine in children and adolescents. This scale has a total of 48 items.
The ten items that reflect emotional well-being were selected to measure changes over time from
a patient, parent, and physician perspective.
Results:  421 patients were treated with atomoxetine. 355 patients completed the 8-week
treatment period, and 260 patients completed the 24-week treatment period. The ten items that
reflect emotional well-being were grouped in five dimensions: depressed mood, self-harm,
irritability/agitation, drowsiness, and euphoria. The scores of these dimensions decreased over
time, both from a patient as well as from a parent and physician perspective. Only the dimension
self-harm was extremely low at baseline and stayed low over time. The mean scores for the ten
items depended on the rater perspective.
Conclusion: The emotional well-being of children and adolescents with ADHD improved in terms
of depressed mood, irritability/agitation, drowsiness, and euphoria during treatment with
atomoxetine for up to 24 weeks.
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Background
Attention-deficit/hyperactivity disorder (ADHD) is a dis-
order characterized by inattention, impulsivity, and
hyperactivity that affects 3–7% of school-age children [1].
ADHD is usually associated with significant impairment
of cognitive and psychosocial functioning [2,3] and can
have a significant impact on the emotional well-being [4-
6] and the quality of life (QoL) of both patients and their
families [7-12].
Psychostimulants and behavioral therapy are known to be
effective in the treatment of ADHD, as reported in the
MTA study [13]. Atomoxetine is a non-stimulant treat-
ment option for ADHD [14,15], for which efficacy and
tolerability in children and adolescents have been demon-
strated in a number of randomized, placebo-controlled
trials [16-19], supported by a recent meta-analysis [20]. In
most of these studies, questionnaires such as the ADHD-
Rating Scale (ADHD-RS) [21,22] or the Clinical Global
Impression (CGI) [23,24] have been used as outcome
measures for the core symptoms of ADHD. Other ques-
tionnaires such as the Child Health Questionnaire (CHQ)
[25] or the Child Health and Illness Profile, Child Edition
(CHIP-CE) [26] assess aspects of ADHD that go beyond
the core symptoms of the disorder and reflect various
dimensions of health-related quality of life. However,
such questionnaires are often rated by the investigator
alone, resulting in an assessment from one perspective
only. Therefore, several studies have attempted to com-
pare the perspectives of the various individuals involved,
such as the patient, the parent, or the physician, as these
perspectives have been shown to differ [12,27]. The newly
devised Global Impression of Perceived Difficulties
(GIPD) is one such instrument with which the three per-
spectives can be compared [28,29]. The Pediatric Adverse
Event Rating Scale (PAERS) also allows the comparison
between patient, parent, and physician perspectives,
although it was designed to capture the tolerability of
medication rather than efficacy [30].
This report is based on a secondary analysis of data from
two almost identical multi-center, single-arm, open-label
studies in two different age groups (children and adoles-
cents). These studies were designed to investigate the
quality of life in patients with ADHD treated with atom-
oxetine as reflected by the degree of difficulties perceived
by patients, parents and physicians [28,29]. The two stud-
ies were undertaken to address the need for further
research on evidence-based psychopharmacological treat-
ments in children and adolescents [31]. One of the aims
of the two studies on which this post-hoc analysis is based
[28,29] was to assess the tolerability of atomoxetine in
these patients and compare the tolerability as perceived
from the three perspectives (patient, parent, physician)
using the Pediatric Adverse Event Rating Scale (PAERS).
The PAERS is a 48-item questionnaire designed to assess
any type of adverse event occurring in pediatric patients
who are treated with psychotropic medication, especially
as participant in clinical trials, and was developed as part
of the Child and Adolescent Psychiatry Trials Network
(CAPTN) [30,32-34]. The response captures the severity of
48 adverse event items on a five-point Likert scale (0–4).
The main assumption of this post-hoc analysis was that 10
of the 48 items of the PAERS are directly related to the
patients' emotional state and can therefore be considered
to reflect the patient's emotional well-being. Based on this
assumption, the hypothesis of this analysis was that the
emotional well-being of children and adolescents with
ADHD responds well to treatment with atomoxetine as
reflected by the 10 items of the PAERS directly related to
the patient's emotional state. Differences between the
three perspectives (patient, parent, physician) were also
explored.
Methods
Study design and procedures
This is a secondary analysis of data from two almost iden-
tical multi-center, single-arm, open-label studies in two
different age groups (children and adolescents) that were
designed to investigate the quality of life in patients with
ADHD treated with atomoxetine as reflected by the degree
of difficulties perceived by patients, parents and physi-
cians [28,29]. Patients were recruited from child and ado-
lescent psychiatric and pediatric practices and outpatient
clinics throughout Germany. Patients aged 6–17 years
with ADHD as defined in the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text Revi-
sion (DSM-IV-TR) [1] were eligible for the studies. The
diagnosis was confirmed using the "Diagnose-Checkliste
Hyperkinetische Störungen" (Diagnostic Checklist for
Hyperkinetic Disorders), a structured instrument which is
routinely used for the diagnostic assessment of ADHD in
Germany [35]. The items of this instrument correspond to
those of the ADHD-RS [21,22]. Patients had to have an IQ
of ≥70 based on the clinical judgment of the investigator.
The exclusion criteria included clinically significant
abnormal laboratory findings, acute or unstable medical
conditions, cardiovascular disorder, history of seizures,
pervasive developmental disorder, psychosis, bipolar dis-
order, suicidal ideation, any medical condition that might
increase sympathetic nervous system activity, or the need
for psychotropic medication other than study drug.
Patients already being treated with atomoxetine were also
excluded. Other previous treatments were allowed, pro-
vided they were discontinued prior to enrolment in the
study. The protocol was approved by an ethics committee,
and the study was conducted in accordance with the prin-
ciples of the Declaration of Helsinki. Following a wash-
out period, baseline assessments were carried out with allChild and Adolescent Psychiatry and Mental Health 2008, 2:11 http://www.capmh.com/content/2/1/11
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the instruments used. During the first week of treatment,
the patients received atomoxetine at a dose of approxi-
mately 0.5 mg/kg body weight (BW) per day. During the
following 7 weeks, the recommended target dose was 1.2
mg/kg BW per day, but could be adjusted within a range
of 0.5–1.4 mg/kg BW per day, depending on effectiveness
and tolerability. Medication was given once a day in the
morning. Assessments were carried out weekly during the
first two weeks of treatment, and every two weeks thereaf-
ter. After the 8 week treatment period, the physicians
decided in accordance with the patients and their parents
whether the patient was to continue treatment for addi-
tional 16 weeks. Those who participated in this extension
period continued on the same atomoxetine dose which
again could be adjusted within a range of 0.5–1.4 mg/kg
BW per day as considered appropriate by the physician.
During the extension period, three assessments were car-
ried out, after 12, 16, and 24 weeks after baseline. The fol-
lowing instruments were used to assess efficacy: Global
Impression of Perceived Difficulties (GIPD), Attention-
Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS),
Clinical Global Impression-Severity (CGI-S), and the
Weekly Rating of Evening and Morning Behavior –
Revised (WREMB-R). The results from these scales have
been published elsewhere [28,29].
In order to assess the tolerability of atomoxetine in more
detail than is possible using spontaneous adverse event
reports, the Pediatric Adverse Event Rating Scale (PAERS)
[30] was used in the two studies reported here. The data
from both studies were combined and analyzed together.
Tolerability assessments included monitoring vital signs
at every visit and recording all spontaneously reported
adverse events, followed by a systematic elicitation of any
further adverse events using the PAERS. First, the physi-
cian asked an open question as to any adverse events.
Then, the patient and the parent (or other primary car-
egiver) filled out the PAERS independently and without
any interference by the physician. Both the patient and the
parent had to rate each adverse event in terms of how
bothersome or how much of a problem it was during the
past week on a scale from 0 (= not present) to 4 (= a lot).
If the patient was unable to fill out the scale all by him or
her self, an independent person (e. g. a study nurse, but
not the parent or physician) was allowed to provide assist-
ance. As the spontaneous adverse event reports captured
by the physician preceded the elicitation of any further
adverse events using the PAERS, the number of adverse
events captured by these two methods potentially dif-
fered.
Although the PAERS was designed to measure adverse
events, some items are reflecting ADHD symptoms and
difficulties associated with ADHD rather than adverse
events. These items can be expected to improve but not
worsen during ADHD treatment. Of these, all ten items of
the PAERS that were thought to reflect emotional well-
being by face validity were selected for this post-hoc anal-
ysis to measure changes over time.
Noncompliance was defined as missing intake of study
drug on more than five consecutive days, failure to take at
least 70% of study medication for at least two weeks, or
repeated intentional intake of more than the prescribed
dose.
Sample size and statistical analysis
Details on the sample size calculation for the two studies
have been published elsewhere [28,29]. The data of all
patients were evaluated (Full Analysis Set, FAS) using SAS
version 8. The dataset for all analyses of changes from
baseline to endpoint consisted of all patients with a base-
line measurement and at least one post-baseline measure-
ment during the 8-week treatment phase.
Evaluation was largely descriptive. All tests of statistical
significance were carried out at a nominal level of 5%
using two-tailed test procedures. Two-sided confidence
intervals (CIs) were computed using a 95% confidence
level. All inferences regarding statistical significance were
based on comparisons of the 95% confidence intervals
(CI). This is equivalent to significance tests with p-values
and a two-sided α-level of 5%. To avoid correlations of
imputed values, only observed cases (OC) analysis were
performed. No imputation of missing values like last
observation carried forward (LOCF) was applied as the
intention was to describe the patterns for patients still on
medication.
Spearman's correlation coefficients were computed
between all items within each perspective in order to iden-
tify patterns of interdependency among items. This analy-
sis was based on all visits. A sensitivity analysis was done
using the baseline visit only. 95% confidence intervals for
the correlation coefficients were computed based on
Fisher's z-transformation.
Results
Patient population and disposition
Of the 425 patients screened, 421 patients (100%) were
enrolled in the two studies and treated with atomoxetine
[28,29]. All patients were diagnosed with ADHD accord-
ing to DSM-IV criteria. The mean age of the patients was
11.1 years, 338 (80.3%) were boys, 83 (19.7%) were girls.
The 8-week treatment period was completed by 355
(84.3%) patients. 27 (6.4%) of these did not continue
into the extension period because of physician decision.
68 (16.1%) patients discontinued the study between week
8 and week 24. The extension period was completed at
week 24 by 260 (61.8%) patients. The reasons for discon-Child and Adolescent Psychiatry and Mental Health 2008, 2:11 http://www.capmh.com/content/2/1/11
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tinuation at any time during the 24-month observation
period were lack of efficacy (12.4%), parent decision
(6.9%), adverse event (4.8%), protocol violation 3.6%,
patient decision (2.4%), entry criteria exclusion (0.7%),
physician decision (0.7%), and patient lost to follow-up
(0.5%). The patient disposition is shown in Figure 1.
Table 1 shows the patient characteristics. Boys and
patients with the combined subtype ADHD according to
DSM-IV [1] tended to be younger and tended to be diag-
nosed earlier than girls or patients with predominantly
inattentive subtype. 239 (70.7%) of the boys and 39
(47.0%) of the girls were diagnosed with the combined
subtype. The predominantly inattentive subtype was diag-
nosed in 86 (25.4%) of the boys and 38 (45.8%) of the
girls. The subgroups "predominantly hyperactive-impul-
sive subtype" and "ADHD, not otherwise specified" were
small (6 and 13 individuals, respectively). The mean
ADHD-RS total score at baseline was 32.6 [CI 31.5 to
33.6] points. This score decreased to 16.3 [CI 15.1 to 17.5]
points at week 8, and was 14.5 [CI 13.1 to 15.8] points at
the end of week 24.
Pre-existing comorbid conditions were reported for 310
(73.6%) patients, the most frequent being psychiatric
comorbidities, specifically conduct disorder (19.7%),
oppositional defiant disorder (17.6%), enuresis (4.3%),
tic disorder (2.4%), emotional disorder of childhood
(2.6%), and depression (1.4%). Physical comorbidities
that were reported at a rate of >2% were headache (5.7%),
seasonal allergy (4.3%), asthma (3.3%), neurodermatitis
(2.6%), acne (2.4%), upper respiratory tract infection
(2.1%), and rhinitis (2.1%).
349 (82.9%) of the 421 patients had previously been
treated for ADHD. The percentage was similar for the pre-
dominantly inattentive subtype (N = 101, 81.5%) and the
combined subtype (N = 231, 83.1%). Medications most
frequently used before study entry were short-acting
methylphenidate (N = 290, 68.9%), long-acting methyl-
phenidate (N = 196, 46.6%), amphetamines (N = 56,
13.3%), antipsychotic drugs (N = 12, 2.9%) and herbal/
complementary therapies (N = 10, 2.4%). Commonly
reported non-drug therapies prior to study were: occupa-
Patient disposition Figure 1
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Table 1: Patient characteristics
Age (Years) Age at 1st occurrence of symptoms 
(Years)
Age at 1st ADHD-diagnosis 
(Years)
N (%) Mean SD Mean SD Mean SD
All patients 421 (100) 11.1 2.74 4.0 2.03 8.1 2.59
Boys 338 (80.3) 11.0 2.70 4.0 1.94 7.9 2.54
Girls 83 (19.7) 11.6 2.87 4.3 2.35 8.8 2.70
Combined subtype* 278 (66.0) 10.6 2.58 3.7 1.92 7.6 2.42
Predominantly 
inattentive subtype*
124 (29.5) 12.4 2.59 4.7 1.93 9.2 2.58
Predominantly 
hyperactive-impulsive 
subtype*
6 (1.4) 8.6 2.33 4.2 2.01 6.6 2.22
ADHD, not otherwise 
specified *
13 (3.1) 11.7 3.08 4.8 3.42 9.6 2.30
* According to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.
Abbreviations: SD = standard deviation.Child and Adolescent Psychiatry and Mental Health 2008, 2:11 http://www.capmh.com/content/2/1/11
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tional therapy (N = 48, 11.4%), "other" psychotherapy (N
= 31, 7.4%), structured psychotherapy (N = 42, 10.0%),
and remedial education (N = 10, 2.4%). The most fre-
quent reason for discontinuation of previous therapy in
patients with pre-treatment was inadequate response (N =
216, 61.9%). N = 68 patients (16.2%) discontinued previ-
ous therapy because of adverse events.
The mean atomoxetine dose given during the first week of
treatment was 0.50 mg/kg per BW day (SD 0.07, range
0.40 – 0.80 mg/kg BW per day). Thereafter, the mean dose
for the respective visit intervals ranged between 1.17 and
1.18 mg/kg per day (min. 0.40, max. 1.50 mg/kg per day).
Compliance as defined above was present in 91.2% of all
patients over the course of the entire study.
Concomitant medication was taken by 272 (64.6%) of
the patients. Cough and cold remedies, analgesics, antibi-
otics and herbal/complementary medicines were given
most frequently. Whilst continuous medication with any
psychotropic compound other than the study medication
led to discontinuation of the patient in the study, 3.8% (N
= 16) of patients did receive a psychotropic medication at
least once over the entire course of the 24-week study. The
medication included compounds such as St. John's Wort,
imipramine or a benzodiazepine. Concomitant behavio-
ral therapy was given to 27 (6.4%) patients, and 20
(4.8%) patients received additional occupational therapy.
Results from ten items of the PAERS
The following ten items of the Pediatric Adverse Event Rat-
ing Scale (PAERS) were selected to investigate emotional
well-being: "feeling withdrawn or numb" (item 8), "nerv-
ous, tense, or uptight" (item 16), "trying to hurt him or
her self" (item 20), "feeling restless or keyed up" (item
26), "sad or low mood/unhappy" (item 32), "drowsy or
'out of it"' (item 37), "unusually good mood/super
happy" (item 38), "not interested/no enthusiasm" (item
39), "angry or irritable/in a bad mood" (item 42), and
"thinking about or wanting to hurt self" (item 43). Each
of these items was rated from three perspectives (patient,
parent, and physician) like all PAERS items. If present, the
severity of the respective behavior or emotional state was
rated on a 5 point Likert scale (0 = not present, 1 = mild,
2 = moderate, 3 = severe, and 4 = extreme).
The following five groups of items were identified, whose
correlations were larger than 0.4 between items: (a) items
relating to depressed mood (items 8, 32, and 39), (b)
items relating to self-harm (items 20 and 43), (c) items
relating to irritability/agitation (items 16, 26, and 42), (d)
one item relating to drowsiness (item 37), and (e) one
item relating to euphoria (item 38) (Table 2). The correla-
tion of the various items in the five groups is shown in
Table 3.
Table 2: Groups of items of the Pediatric Adverse Event Rating 
Scale (PAERS) used to assess emotional well-being
Item No. Item Groups
Items relating to depressed mood
8 Feeling withdrawn or numb
32 Sad or low mood/unhappy
39 Not interested/no enthusiasm
Items relating to self-harm
20 Trying to hurt him or her self
43 Thinking about or wanting to hurt self
Items relating to irritability/aggression
16 Nervous, tense, or uptight
26 Feeling restless or keyed up
42 Angry or irritable/in a bad mood
Item relating to drowsiness
37 Drowsy or "out of it"
Item relating to euphoria
38 Unusually good mood/super happy
Table 3: The five groups of items from the Pediatric Adverse 
Event Rating Scale (PAERS) whose Spearman's correlation 
coefficients for the physician rating were larger than 0.4 between 
items (all visits pooled; 3611 observations).
Items relating to depressed mood (items 8, 32, and 39)
a. Correlation of items, physician rated
item 8 vs. item 32 r = 0.448 (95% CI 0.421 to 0.473)
item 8 vs. item 39 r = 0.413 (95% CI 0.385 to 0.439)
item 32 vs. item 39 r = 0.465 (95% CI 0.439 to 0.490)
b. Correlation of items, parent rated
item 8 vs. item 32 r = 0.534 (95% CI 0.510 to 0.557)
item 8 vs. item 39 r = 0.424 (95% CI 0.396 to 0.450)
item 32 vs. item 39 r = 0.444 (95% CI 0.417 to 0.470)
c. Correlation of items, patient rated
item 8 vs. item 32 r = 0.339 (95% CI 0.309 to 0.367)
item 8 vs. item 39 r = 0.313 (95% CI 0.283 to 0.342)
item 32 vs. item 39 r = 0.383 (95% CI 0.355 to 0.411)
Items relating to self-harm (items 20 and 43)
d. correlation of items, physician rated
item 20 vs. item 43 r = 0.606 (95% CI 0.585 to 0.626)
e. correlation of items, parent rated
item 20 vs. item 43 r = 0.659 (95% CI 0.640 to 0.677)
f. correlation of items, patient rated
item 20 vs. item 43 r r = 0.598 (95% CI 0.576 to 0.618)
Items relating to irritability/agitation (items 16, 26, and 42)
g. Correlation of items, physician rated
item 16 vs. item 26 r = 0.478 (95% CI 0.453 to 0.503)
item 16 vs. item 42 r = 0.459 (95% CI 0.433 to 0.484)
item 26 vs. item 42 r = 0.471 (95% CI 0.445 to 0.496)
h. Correlation of items, parent rated
item 16 vs. item 26 r = 0.539 (95% CI 0.515 to 0.562)
item 16 vs. item 42 r = 0.516 (95% CI 0.492 to 0.540)
item 26 vs. item 42 r = 0.533 (95% CI 0.509 to 0.556)
i. Correlation of items, patient rated
item 16 vs. item 26 r = 0.367 (95% CI 0.338 to 0.395)
item 16 vs. item 42 r = 0.353 (95% CI 0.324 to 0.381)
item 26 vs. item 42 r = 0.379 (95% CI 0.350 to 0.406)
Item relating to drowsiness (item 37)
Item relating to euphoria (item 38)Child and Adolescent Psychiatry and Mental Health 2008, 2:11 http://www.capmh.com/content/2/1/11
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In general, the correlations were moderate to high only for
parent and physician ratings, but not for patient ratings.
The pattern of moderate to high correlations was similar
between parent and physician ratings. In the sensitivity
analyses using baseline ratings only (rather than all rat-
ings), the correlations were generally lower, but con-
firmed the overall pattern of correlations based on the
other points in time. A total score of all the items was not
calculated as correlations were low between items that
belonged to different groups (Table 2). These correlations
are not reported here.
Items relating to depressed mood
Based on the confidence intervals at baseline, the parent
ratings of the items "feeling withdrawn or numb" (item
8), "sad or low mood/unhappy" (item 32), and "not inter-
ested/no enthusiasm" (item 39), were significantly higher
compared to both the patients and the physician ratings,
which were similar. However, mean scores for all items
were below 0.81 (Table 4). The scores for the items relat-
ing to depressed mood decreased over time. The mean
change from baseline was statistically significant for all
three items and all three perspectives both at week 8 and
at week 24 (Table 4). Generally, there was a tendency for
mean scores to decrease further the longer patients stayed
on medication. Moreover, the decrease in scores was gen-
erally most pronounced in parent ratings, followed by
patient and physician ratings.
Table 4: Baseline ratings and change from baseline at weeks 8 and 24
Item Week Physician rating Parent rating Patient rating
Mean 95% CI SD Mean 95% CI SD Mean 95% CI SD
Items relating to depressed mood
8 0 0.32 0.26 to 0.39 0.71 0.54 0.45 to 0.63 0.93 0.33 0.26 to 0.40 0.75
Ch 8 -0.14 -0.22 to -0.05 0.77 -0.25 -0.35 to -0.15 0.96 -0.20 -0.28 to -0.12 0.76
Ch 24 -0.20 -0.29 to -0.11 0.71 -0.33 -0.45 to -0.21 0.97 -0.23 -0.32 to -0.13 0.75
32 0 0.50 0.42 to 0.58 0.83 0.81 0.71 to 0.91 1.04 0.44 0.34 to 0.53 0.95
Ch 8 -0.18 -0.28 to -0.09 0.87 -0.31 -0.43 to -0.19 1.08 -0.23 -0.34 to -0.12 0.99
Ch 24 -0.26 -0.37 to -0.15 0.90 -0.44 -0.57 to -0.31 1.10 -0.15 -0.28 to -0.02 1.03
39 0 0.48 0.40 to 0.57 0.91 0.78 0.68 to 0.89 1.07 0.47 0.38 to 0.56 0.94
Ch 8 -0.17 -0.27 to -0.07 0.90 -0.28 -0.40 to -0.16 1.11 -0.28 -0.38 to -0.18 092
Ch 24 -0.28 -0.39 to -0.17 0.90 -0.36 -0.49 to -0.22 1.14 -0.31 -0.43 to -0.19 1.01
Items relating to self-harm
20 0 0.07 0.03 to 0.10 0.38 0.11 0.06 to 0.16 0.51 0.08 0.04 to 0.11 0.40
Ch 8 -0.01 -0.05 to 0.03 0.37 -0.02 -0.07 to 0.02 0.43 0.00 -0.05 to 0.06 0.51
Ch 24 -0.02 -0.06 to 0.02 0.32 -0.03 -0.09 to 0.02 0.42 -0.02 -0.06 to 0.02 0.34
43 0 0.07 0.03 to 0.10 0.37 0.11 0.06 to 0.16 0.52 0.08 0.04 to 0.12 0.40
Ch 8 -0.02 -0.07 to 0.03 0.44 -0.01 -0.06 to 0.04 0.47 0.02 -0.02 to 0.06 0.37
Ch 24 -0.02 -0.06 to 0.03 0.37 -0.03 -0.08 to 0.01 0.39 0.00 -0.05 to 0.05 0.42
Items relating to irritability/agitation
16 0 0.98 0.87 to 1.08 1.10 1.27 1.16 to 1.39 1.20 0.61 0.51 to 0.70 1.01
Ch 8 -0.68 -0.80 to -0.55 1.17 -0.78 -0.91 to -0.65 1.18 -0.36 -0.48 to -0.25 1.07
Ch 24 -0.69 -0.83 to -0.55 1.16 -0.80 -0.94 to -0.65 1.19 -0.41 -0.54 to -0.27 1.10
26 0 1.41 1.30 to 1.53 1.22 1.79 1.67 to 1.92 1.27 0.66 0.56 to 0.77 1.09
Ch 8 -0.97 -1.10 to -0.83 1.24 -1.09 -1.24 to -0.95 1.34 -0.42 -0.52 to -0.31 1.00
Ch 24 -0.93 -1.07 to -0.79 1.18 -1.10 -1.26 to -0.94 1.31 -0.43 -0.56 to -0.30 1.08
42 0 1.32 1.20 to 1.45 1.26 2.00 1.88 to 2.12 1.22 0.93 0.81 to 1.04 1.22
Ch 8 -0.52 -0.64 to -0.39 1.17 -0.72 -0.86 to -0.57 1.34 -0.43 -0.57 to -0.29 1.26
Ch 24 -0.55 -0.70 to -0.41 1.18 -0.85 -1.02 to -0.68 1.38 -0.46 -0.62 to -0.30 1.33
Item relating to drowsiness
37 0 0.25 0.19 to 0.30 0.61 0.43 0.35 to 0.50 0.81 0.40 0.32 – 0.48 0.85
Ch 8 -0.08 -0.15 to 0.00 0.71 -0.16 -0.25 to -0.07 0.83 -0.16 -0.26 to -0.07 0.88
Ch 24 -0.17 -0.24 to -0.10 0.59 -0.25 -0.36 to -0.14 0.88 -0.20 -0.31 to -0.09 0.86
Item relating to euphoria
38 0 0.35 0.28 to 0.43 0.77 0.65 0.55 to 0.74 1.00 1.06 0.93 to 1.19 1.33
Ch 8 -0.14 -0.22 to -0.05 0.83 -0.32 -0.43 to -0.20 1.05 -0.40 -0.56 to -0.25 1.41
Ch 24 -0.15 -0.25 to -0.06 0.75 -0.40 -0.51 to -0.29 0.92 -0.43 -0.58 to -0.28 1.24
Items: 8 = feeling withdrawn or numb; 32 = sad or low mood/unhappy; 39 = not interested/no enthusiasm; 20 = trying to hurt him or her self; 43 = 
thinking about or wanting to hurt self; 16 = nervous, tense, or uptight, 26 = feeling restless or keyed up; 42 = angry or irritable/in a bad mood; 37 = 
drowsy or "out of it, 38 = unusually good mood/super happy. Abbreviations: 0 = Week 0 (Baseline); Ch 8 = change to week 8, Ch 24 = change to 
Week 24; CI = confidence interval; SD = standard deviation.Child and Adolescent Psychiatry and Mental Health 2008, 2:11 http://www.capmh.com/content/2/1/11
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Items relating to self-harm
The scores for the items relating to self-harm were
extremely low at baseline and stayed low over time (Table
4). The scores were comparable in terms of the three per-
spectives. No significant changes were observed compared
to baseline.
Items relating to irritability/agitation
At baseline, a similar pattern was observed for items
"nervous, tense, or uptight" (item 16), "feeling restless or
keyed up" (item 26), and "angry or irritable/in a bad
mood" (item 42). Based on the confidence intervals, the
parent rating was significantly higher than the physician
rating, which was again significantly higher than the
patient rating for all three items. The scores for the items
relating to irritability/agitation decreased over time (Table
4). The decreases from baseline were largest for parents,
followed by physicians and patients: the mean changes
from baseline were statistically significant for all perspec-
tives, all three items, and both at week 8 and week 24, as
shown by non-overlapping confidence intervals.
Item relating to drowsiness
Based on the confidence intervals at baseline, the item
"drowsy or 'out of it"' (item 37) was scored similarly by
parents and patients, and significantly higher than by phy-
sicians. The scores for the item relating to drowsiness
decreased over time (Table 4). Also the changes from
baseline were more pronounced in parent and patient rat-
ings than in physician ratings. The mean changes from
baseline were statistically significant for all perspectives
and both at week 8 and week 24, as shown by non-over-
lapping confidence intervals.
Item relating to euphoria
Based on the confidence intervals at baseline, the item
"unusually good mood/super happy" (item 38) was
scored significantly higher by patients than by parents,
and significantly higher than by physicians. The scores for
the item relating to euphoria decreased over time (Table
4). The changes from baseline were scored similarly by
patients and physicians, but the decreases were smaller in
the physician rating. The mean changes from baseline
were statistically significant in terms of all three perspec-
tives and were significant both at week 8 and week 24, as
shown by non-overlapping confidence intervals.
Discussion
The aim of this post-hoc analysis was to evaluate the
scores of the ten items of the Pediatric Adverse Event Rat-
ing Scale (PAERS) that were considered to be related to
emotional well-being by face validity. Each of these ten
items was rated from three perspectives: the patient, the
parent, and the physician perspective. These perspectives
were subsequently compared in terms of the height of
scores and changes in the scores over time.
Emotional well-being as reflected by the scores on the
respective ten items of the PAERS showed both similari-
ties as well as differences both regarding the course of the
scores over time and comparisons between the three per-
spectives (patient, parent, physician). Generally, scores
for all items rated from all three perspectives decreased
over the 24-week duration of the two studies. Thus, emo-
tional well-being as reflected by the scores on the ten
items of the PAERS was seen to improve during treatment
with atomoxetine.
Correlations between parent and physician scores were
generally higher than correlations between parent and
patient scores as well as correlations between physician
and patient scores. There were, however, distinct differ-
ences between the patterns observed for the five groups of
items relating to depressed mood, self-harm, irritability/
agitation, drowsiness, and euphoria.
For the items relating to depressed mood, parent ratings
resulted in higher scores than either patient or physician
ratings at baseline. This may be due to parents being par-
ticularly concerned about the emotional well-being of
their children. Over time, however, there is a reduction in
the scores for these items from all three rater perspectives.
Obviously, all individuals concerned recognize an
improvement in the emotional well-being of the patients
over time. Surprisingly, both patient and physician ratings
on the PAERS were similar, although children and adoles-
cents seemed to dissimulate their difficulties or failed to
perceive their difficulties correctly according to the Global
Impression of Perceived Difficulties (GIPD), whilst physi-
cians perceived the child's difficulties as being considera-
bly greater [28,29]. Mean changes for most items and
ratings were approximately one third of a standard devia-
tion (Table 4). This can be considered a moderate change,
given the low scores at baseline.
For the items relating to self-harm, scores from all three
perspectives were very low at baseline and did not change
significantly whilst the child or adolescent is being treated
with atomoxetine. Mean changes from baseline for these
items and ratings were negligible. This finding is encour-
aging, because it suggests that attempts to self-harm or
thoughts of self-harm are not aggravated by treatment
with atomoxetine.
For the items relating to irritability/agitation, scores dif-
fered significantly depending on the rater. Whilst baseline
scores rated by parents were the highest, baseline scores
rated by patients were lowest, and baseline scores rated by
physicians were in between. These findings may be due toChild and Adolescent Psychiatry and Mental Health 2008, 2:11 http://www.capmh.com/content/2/1/11
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the high impact that a child's irritability/agitation may
have on the parents. The physician may be less likely to
observe irritability/agitation than a parent might, and
children or adolescents seemed to dissimulate their diffi-
culties in these two studies [28,29]. Mean changes for
most items in this dimension and for physician and par-
ent ratings were greater than one half of the standard devi-
ation (Table 4). This is a considerable change. In contrast,
the patient ratings for these items changed to a smaller
degree. This finding may be a result of the lower patient-
rated scores at baseline.
The scores for the item relating to drowsiness as rated by
patients and parents were similar whilst the scores rated
by the physicians differed from the scores rated either by
the patients or the parents at baseline. Physician-rated
baseline scores were lower, which may be due to the phy-
sicians not having as much opportunity to witness any
drowsiness as parents may do. Patients can be expected to
experience this well-known adverse event related to atom-
oxetine [36]. Mean changes for this item were just below
one third of the standard deviation. This can be consid-
ered a moderate change, given the low scores at baseline.
The scores for the item relating to euphoria differed
between all three perspectives (patient, parent, physi-
cian). Whilst patient ratings resulted in the highest scores
for euphoria, the scores from physician ratings were the
lowest and scores from parent ratings were in between.
The greater euphoria experienced by the patients com-
pared to the euphoria seen by the parents or physicians
seems to correspond to the lower degree of ADHD-related
difficulties perceived by patients compared to the parent
or physician perspectives as measured by the GIPD in
these two studies [28,29]. The rating of euphoria by the
parents may have resulted in scores that more objectively
reflect the actual situation, whilst the physicians may not
have had adequate opportunity to witness the euphoria
before carrying out their rating. Mean changes for this
item were approximately one third of the standard devia-
tion. This can be considered a moderate change, given the
low to moderate scores at baseline.
This study has several limitations. Most importantly, the
study did not include a placebo control, so that the degree
to which the results reflect drug-specific effects cannot be
determined definitely. More specifically, placebo-control-
led studies would be needed to distinguish direct medica-
tion effects on emotional well-being from indirect effects
caused by improvement of core symptoms. Furthermore,
the age-distribution of the sample does not reflect the age-
distribution of individuals with ADHD in the general
pediatric population. This is due to the fact that this anal-
ysis is based on two studies, one in children and one in
adolescents. Whilst the age-distribution is normal within
each of the two otherwise identical studies, the age-distri-
bution of the combined samples is not quite normal, as it
shows two peaks. Due to the open-label design, unspecific
factors such as rater bias, expectation effects, and time
effects cannot be ruled out. However, this does not auto-
matically compromise the validity of the results [37]. Fur-
thermore, although both mean symptom reduction and
improvement in emotional well-being were considerable,
the results do not allow direct comparison against
changes of these parameters upon treatment with other
ADHD medications. Treatment emergent adverse events
occurring in the two studies on which this analysis is
based have been reported and discussed elsewhere in
more detail [28,29]. For evaluating the adverse event pro-
file, it needs to be taken into account that only those
patients for whom the physician decided to continue ato-
moxetine treatment at week 8 were followed for addi-
tional 16 weeks until week 24.
Taken together, these findings could be expected, as cog-
nition and the regulation of emotion are known to influ-
ence one another [38]. Furthermore, cognitive control of
emotion involves frontal structures of the brain [39], areas
of the brain that play an important role in the pathophys-
iology of ADHD [3]. Thus, any pharmacological treat-
ment that is effective on the core symptoms of ADHD and
executive functioning can also be expected to improve the
emotional regulation and thus the emotional well-being
of patients with ADHD. This hypothesis is supported by
the findings from this secondary analysis. These findings
appear particularly relevant in face of the important role
that emotional regulation plays in children, adolescents,
and adults with ADHD [4,5,39-43].
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